KWS BioTest will be exhibiting so meet us at our booth in the ECD section to learn more about our clinical biomarker offering.
KWS BioTest's CSO Professor Neil Williams will be speaking at the event on;
Cell-based biomarkers as a means of confirming target engagement and mechanism in early clinical trials
- The use of PD biomarkers in early clinical trials has the potential to substantially de-risk projects and enhance value
- For many novel therapeutics, soluble analytes are not sufficient as suitable markers of mechanism and proof of concept
- While the use of cell based markers, and even functional assays, is logistically challenging, with suitable validation and expertise they can provide high quality confirmation of effect
- By applying an ‘intelligent design’ approach from project initiation, KWS can determine therapeutic and potential toxicological effects of novel therapeutics on immune function in the clinic, adding value to development candidates
If you would like more information then please contact us.